Relationship between neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with the severity of COVID-19

Ida A Arini1, Sri Masyeni2, Ni W Widhidewi3

  • 1Faculty of Medicine and Health Sciences, Universitas Warmadewa, Denpasar, Indonesia.

Narra J
|May 27, 2024
PubMed

Insights

Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can predict COVID-19 severity. Higher NLR and PLR levels correlate with more severe disease, offering valuable insights for patient assessment.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Biomarkers

Background:

  • Coronavirus disease 2019 (COVID-19) presents a significant global health challenge, particularly for vulnerable populations.
  • Inflammatory biomarkers, such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), have shown potential in assessing infection severity.

Purpose of the Study:

  • To investigate the association between NLR and PLR and the severity of COVID-19.
  • To evaluate the predictive value of NLR and PLR in distinguishing between moderate and severe/critical COVID-19 cases.

Main Methods:

  • A cross-sectional study involving 104 COVID-19 patients (aged 18-50, no comorbidities) was conducted.
  • Patients were classified into moderate and severe/critical groups based on clinical presentation.
  • The Mann-Whitney test was employed to analyze the relationship between NLR, PLR, and COVID-19 severity.

Main Results:

  • A significant correlation was found between elevated NLR (p=0.002) and PLR (p=0.001) and increased COVID-19 severity.
  • Optimal cut-off values were identified: NLR ≥3.8 (95% sensitivity, 74% specificity) and PLR ≥106 (70% sensitivity, 50% specificity).
  • The majority of patients (77.9%) presented with moderate COVID-19 severity.

Conclusions:

  • NLR and PLR demonstrate a strong association with COVID-19 severity.
  • These ratios serve as promising, accessible biomarkers for predicting disease progression and patient outcomes.
  • Further research can explore integrating NLR and PLR into routine clinical assessments for COVID-19 management.